Log in

Spark Therapeutics Stock Price, Forecast & Analysis (NASDAQ:ONCE)

$111.37
-0.20 (-0.18 %)
(As of 11/14/2019 08:00 AM ET)
Today's Range
$110.75
Now: $111.37
$111.79
50-Day Range
$96.56
MA: $103.13
$111.69
52-Week Range
$34.53
Now: $111.37
$114.20
Volume443,400 shs
Average Volume686,776 shs
Market Capitalization$4.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.08
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.72 million
Book Value$8.99 per share

Profitability

Net Income$-78,820,000.00
Net Margins-358.41%

Miscellaneous

Employees368
Market Cap$4.29 billion
Next Earnings Date11/19/2019 (Estimated)
OptionableOptionable

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.


Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) issued its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.34. The biotechnology company had revenue of $25.19 million for the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative return on equity of 59.10% and a negative net margin of 358.41%. View Spark Therapeutics' Earnings History.

When is Spark Therapeutics' next earnings date?

Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 19th 2019. View Earnings Estimates for Spark Therapeutics.

What price target have analysts set for ONCE?

11 brokerages have issued 1 year price objectives for Spark Therapeutics' stock. Their forecasts range from $47.00 to $115.00. On average, they anticipate Spark Therapeutics' share price to reach $106.00 in the next twelve months. This suggests that the stock has a possible downside of 4.8%. View Analyst Price Targets for Spark Therapeutics.

What is the consensus analysts' recommendation for Spark Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 11 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:
  • 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/14/2019)
  • 2. William Blair analysts commented, "We see a sound strategic fit with Roche given its recent investment in hemophilia with the launch of Hemlibra (SPK-8011 in hemophilia A, SPK-8016 in hemophilia A patients with inhibitors and royalties from the fidanacogene elaparvovec collaboration with Pfizer), ophthalmology (Luxturna in the United States and royalties from the Luxturna EU launch), and neuroscience (SPK-1001 for CLN2) franchises." (2/26/2019)

Has Spark Therapeutics been receiving favorable news coverage?

News articles about ONCE stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Spark Therapeutics earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Spark Therapeutics.

Are investors shorting Spark Therapeutics?

Spark Therapeutics saw a drop in short interest in October. As of October 31st, there was short interest totalling 3,540,000 shares, a drop of 12.4% from the September 30th total of 4,040,000 shares. Based on an average daily volume of 529,700 shares, the short-interest ratio is presently 6.7 days. Currently, 10.2% of the company's stock are short sold. View Spark Therapeutics' Current Options Chain.

Who are some of Spark Therapeutics' key competitors?

What other stocks do shareholders of Spark Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Micron Technology (MU), Celgene (CELG), Netflix (NFLX) and bluebird bio (BLUE).

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)
  • Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)
  • Mr. Stephen W. Webster, Chief Financial Officer (Age 58)
  • Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)
  • Mr. Daniel R. Faga, Chief Bus. Officer (Age 39)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who are Spark Therapeutics' major shareholders?

Spark Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Gabelli Funds LLC (1.40%), ARP Americas LP (0.93%), GABELLI & Co INVESTMENT ADVISERS INC. (0.67%), SG Americas Securities LLC (0.45%), Gamco Investors INC. ET AL (0.32%) and Havens Advisors LLC (0.21%). Company insiders that own Spark Therapeutics stock include Hospital Of Philade Children's, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.

Which institutional investors are selling Spark Therapeutics stock?

ONCE stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Gamco Investors INC. ET AL, GABELLI & Co INVESTMENT ADVISERS INC., Rhumbline Advisers, Mackay Shields LLC and Strs Ohio. View Insider Buying and Selling for Spark Therapeutics.

Which institutional investors are buying Spark Therapeutics stock?

ONCE stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, ARP Americas LP, Havens Advisors LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Nisa Investment Advisors LLC, Syquant Capital Sas and Tower Research Capital LLC TRC . View Insider Buying and Selling for Spark Therapeutics.

How do I buy shares of Spark Therapeutics?

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $111.37.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $4.29 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe.View Additional Information About Spark Therapeutics.

What is Spark Therapeutics' official website?

The official website for Spark Therapeutics is http://www.sparktx.com/.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  493 (Vote Outperform)
Underperform Votes:  412 (Vote Underperform)
Total Votes:  905
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Featured Article: Federal Reserve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel